<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273661</url>
  </required_header>
  <id_info>
    <org_study_id>NEBULAMB</org_study_id>
    <nct_id>NCT02273661</nct_id>
  </id_info>
  <brief_title>Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).</brief_title>
  <acronym>NEBULAMB</acronym>
  <official_title>Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <brief_summary>
    <textblock>
      Compare the incidence of severe clinical exacerbations in the treatment of ABPA, between a&#xD;
      strategy with a maintenance treatment and a conventional strategy without antifungal&#xD;
      maintenance therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 19, 2014</start_date>
  <completion_date type="Actual">June 28, 2019</completion_date>
  <primary_completion_date type="Actual">June 28, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of first severe clinical exacerbation</measure>
    <time_frame>within 24 months following the attack treatment,</time_frame>
    <description>Occurrence of severe clinical exacerbation within 24 months following attack treatment, defined by the onset or worsening of dyspnea aggravating the baseline condition that justified:&#xD;
-increased inhalation treatments (inhaled bronchodilators and / or corticosteroids)&#xD;
and / or initiation of systemic corticosteroid treatment&#xD;
and / or hospitalization&#xD;
AND persisting for more than 7 days.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Allergic Bronchopulmonary Aspergillosis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An aerosol of isotonic saline x 1/ week will be administered during 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ambisome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal amphotericin B (Ambisome®)</intervention_name>
    <description>An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months</description>
    <arm_group_label>Ambisome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>An aerosol of isotonic saline x 1/ week will be administered during 6 months</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients with ABPA justifying an attack treatment with corticosteroids and itraconazole&#xD;
        and combining the following criteria:&#xD;
&#xD;
          1. atopic subject or a history of asthma , history of total Immunoglobin E (IgE)&gt; 417 kU&#xD;
             / L (or &gt; 210 kU / L with a clear worsening) of a known ABPA), specific Immunoglobin E&#xD;
             against Aspergillus fumigatus positive ( &gt;0.35 KUA/L) or positive skin tests.&#xD;
&#xD;
          2. associated with two other of the following criteria: documentation of precipitating&#xD;
             antibodies or Immunoglobulin G positive to Aspergillus fumigatus, of radiological&#xD;
             infiltrates associated with ABPA (transitional / persistent / bronchial dilation), of&#xD;
             blood eosinophilia &gt; 500 elements/mm3.&#xD;
&#xD;
          3. After informing and obtaining consent signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of childbearing age who do not have an effective contraception for at least 12&#xD;
             first months of the study( 10 months + 2 months of treatment washout) pregnant or&#xD;
             lactating women,&#xD;
&#xD;
          -  Patient with cystic fibrosis&#xD;
&#xD;
          -  Patient with a contra-indication to itraconazole&#xD;
&#xD;
          -  Intolerance to β2 -agonists&#xD;
&#xD;
          -  Known hypersensitivity to liposomal amphotericin B or any other component&#xD;
&#xD;
          -  Laboratory abnormalities: significant abnormalities of platelet blood count , liver&#xD;
             function tests (SGPT, SGOT(serum glutamate oxaloacetate transaminase) , total&#xD;
             bilirubin &gt; 5 times the upper limit of the normal range )&#xD;
&#xD;
          -  severe renal function impairment (creatinine clearance enf to 30 ml/min)&#xD;
&#xD;
          -  Concomitant use of one or more of the following treatments: Alfuzosine, alcaloïdes de&#xD;
             l'ergot de seigle vasoconstricteur, aliskiren, astemizole, atorvastatine, avanafil,&#xD;
             association Ombitasvir and Paritaprevir, Bepridil, Cisaprid, Dabigatran, dapoxetin,&#xD;
             domperidon, dronedaron, Eplerenone, Halofantrin, Ivabradin, Lomitapid, lurasidon,&#xD;
             Millepertuis, mizolastin, Pimozid,Quétiapin, quinidin, Ranolazine, ritonavir,&#xD;
             Sertindole, sildénafil, simvastatin, sirolimus, Sultoprid, Terfenadine, ticagrelor,&#xD;
             triazolam Vardénafil (in men over than 75)&#xD;
&#xD;
          -  patient with anti IgE- monoclonal antibody for less than 4 months or with current&#xD;
             complications related to previous treatment with anti IgE- monoclonal antibody -&#xD;
&#xD;
          -  Ventricular dysfunction demonstrated such as congestive heart failure or a history of&#xD;
             congestive heart failure&#xD;
&#xD;
          -  Simple aspergilloma, chronic pulmonary aspergillosis, invasive pulmonary aspergillosis&#xD;
&#xD;
          -  Respiratory infection aggravating asthma or ABPA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chu de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 22, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Aspergillosis, Allergic Bronchopulmonary</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

